One particular study on patients with SAPHO syndrome showed that treatment with Secukinumab, an IL-17 inhibitor, significantly alleviated skin lesions and joint pain, indicating a crucial role of IL-17 in the associated skin manifestations. Here, IL17A is linked to SAPHO syndrome.